RxDoctor Payments Data

Ana Vidal, MD

Internal Medicine · Webster, TXNPI 1124187570

Payments from drug & device makers

$968in general payments, 2019–2025

Across 38 payments — averaging $25.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$278
  • Inspire Medical Systems, Inc.$138
  • Dexcom, Inc.$94
  • Amgen$78
  • AbbVie$67
  • Amarin Pharma, Inc.$48
  • plus $265 from 9 others

What the payments were for

  • Food & beverage$968100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$968 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$18,871
Medicare patients
45
Services billed
237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol90$92,466
OzempicSemaglutide21$39,945
TradjentaLinagliptin20$28,207
JanuviaSitagliptin Phosphate16$22,769
EliquisApixaban16$17,550
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$13,495
MyrbetriqMirabegron13$11,928
JardianceEmpagliflozin12$9,921
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,391
Atorvastatin Calcium166$1,233
Rosuvastatin Calcium115$1,177
Nano 2nd Gen Pen NeedlePen Needle, Diabetic14$1,113
Levothyroxine Sodium118$1,017
Omeprazole52$992
Alcohol PadsAlcohol Antiseptic Pads12$813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$278$92,46690 claims
Novo NordiskOzempic$38$39,94521 claims
GSKTrelegy Ellipta$31$13,49511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →